“Adrian Chew is a rising star partner with a very deep technical understanding, with a technical background in science and the law, and a huge amount of experience from high-profile cases over the years. He has been involved in major LOE cases.” (Legal 500 2027)

Adrian specialises in advising life sciences clients on all issues relating to the enforcement and validity of patents and supplementary protection certificates in the UK and the UPC. He has particular expertise in medical use claims, plausibility, antibody functional claims, Article 3 of the SPC Regulation, and the doctrine of equivalents. Adrian also acts for clients in contractual disputes involving patent rights, both before the High Court and in private international arbitrations.

In addition to his expertise in English proceedings, Adrian frequently assists clients with the coordination of litigation in other jurisdictions, working with law firms in Europe, Korea, India, China and the Middle East. In particular Adrian advises a top five pharmaceutical company in the enforcement of its worldwide patent portfolio for two of its blockbuster drugs.

Adrian’s recent experience includes:

• Celltrion v Novartis & Genentech (omalizumab, Patents Court)
• Sandoz v BMS (apixaban, Patents Court, Court of Appeal)
• Alcon v Aspire & Accord (travoprost, Patents Court, Court of Appeal)
• Teva v Eli Lilly (galcanezumab, Patents Court)
• Warner Lambert v NHS England (pregabalin, Patents Court)
• Actavis v Eli Lilly (atomoxetine, Patents Court)